


**Ken J. Ishii, M.D., Ph.D.**



2017- Director, Center for Vaccine and Adjuvant Research (CVAR), Nat. Inst. of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan  
2015-2017 Director, Department of Research Promotion, Japan  
2010- Professor, Lab. of Vaccine Science, Immunology Frontier Research Center (IFREC), Osaka University, Japan  
Agency for Medical Research and Development (AMED), Japan  
2006-2010 Associate Professor: RIMD & IFReC, Osaka University

2003-2008 Group Leader, Akira Innate Immunity Project, ERATO, JST, Japan.  
1996-2003 Postdoc (-2000) Staff Scientist (2000-2003), IND primary reviewer (2000-2003), Office of Vaccine Research and Review (OVR), Center for Biologics and Evaluation Research (CBER), Food and Drug Administration (FDA), USA.  
1995-1996 Senior Resident, Dep. of Anesthesiology School of Medicine, YCU, Japan  
1993-1995 Resident. School of Medicine, Yokohama City University, Japan  
2003 Ph.D., Grad School of Medicine, Yokohama City University (YCU), Japan  
1993 M.D., School of Medicine, YCU, Japan

*Selected publications*

- 1) Kanuma T et al CD63-mediated antigen delivery into extracellular vesicles via DNA vaccination results in robust CD8+ T cell responses *J. Immunol.* 2017 in press
- 2) Hayashi M, et al. Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines. *EBioMedicine.* 2017 15:127-136.
- 3) Kuroda E et al. Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1 $\alpha$  Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation. *Immunity.* 2016 45(6):1299-1310.
- 4) Kitahata Y et al Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells. *Oncotarget.* 2016 7(31):48860-48869.
- 5) Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. *Int Immunol.* 2016 28(7):329-38.
- 6) Koo CX et al RNA polymerase III regulates cytosolic RNA:DNA hybrids and intracellular microRNA expression. *J Biol Chem.* 2015 290(12):7463-73.
- 7) Temizoz B et al TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. *Eur J Immunol.* 2015 45(4):1159-69.
- 8) Kobiyama K et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. *Proc Natl Acad Sci U S A.* 2014 111(8):3086-91.
- 9) Desmet C and Ishii KJ Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination *Nat Rev Immunol* 2012 12(7):479-91

## **Extra cellular nucleic acids: its recognition of, and regulation by, the immune system**

Ken J. Ishii<sup>1),2)</sup>

- 1) Center for Vaccine and Adjuvant Research (CVAR), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- 2) Lab. Vaccine Science, Immunology Frontier Research Center (IFReC), Osaka University

Contact:

Director,

Center for Vaccine and Adjuvant Research (CVAR)

National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)

7-6-8 Saito-Asagi, Ibaraki, Osaka, Japan 567-0085

Office: +81-72-641-8043 FAX +81-72-641-8079 E-mail: [kenishii@nibiohn.go.jp](mailto:kenishii@nibiohn.go.jp)

Lab HP; <http://www.nibiohn.go.jp/adjuvant/index-e.html>